IPHYFOTCHealthcare · Biotechnology

Innate Pharma S.A.

$2.25+0.00%(+$0.00)

TickerSpark Score

50/100

Mixed

Valuation

Profitability

Growth

Health

Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IPHYF research report →

52-Week Range100% of range

Low $1.31

Current $2.25

High $2.25

Companywww.innate-pharma.com

Innate Pharma S. A. , a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally.

CEO: Jonathan E. Dickinson
IPO: 2015
Employees: 181
HQ: Marseille, FR

Price Chart

+55.17% · this period

Valuation

Market Cap: $211.28M
P/E: -3.64
P/S: 66.04
P/B: -8.25
EV/EBITDA: -3.19
Div Yield: 0.00%

Profitability

Gross Margin: 100.00%
Op Margin: -2058.02%
Net Margin: -1764.51%
ROE: 593.93%
ROIC: -155.52%

Growth & Income

Revenue: $2.79M · -77.93%
Net Income: $-49,158,581 · 0.63%
EPS: $-0.55 · 9.84%
Op Income: $-53,425,000
FCF YoY: -625.61%

Performance & Tape

52W High: $2.25
52W Low: $1.31
50D MA: $1.64
200D MA: $1.94
Beta: 0.81
Avg Volume: 21

Get TickerSpark's AI analysis on IPHYF

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime